Valley National Advisers Inc Alnylam Pharmaceuticals, Inc. Transaction History

Valley National Advisers Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	BUY	$143.31 - $247.0 $1,433 - $2,470	10 Added 66.67%	25 $6,000
Q1 2024 Apr 19, 2024	SELL	$146.51 - $198.2 $10,402 - $14,072	-71 Reduced 82.56%	15 $2,000
Q4 2023 Jan 25, 2024	BUY	$151.41 - $196.57 $1,514 - $1,965	10 Added 13.16%	86 $16,000
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $170 - $211	1 Added 1.33%	76 $13,000
Q2 2023 Jul 31, 2023	BUY	$185.01 - $212.05 $740 - $848	4 Added 5.63%	75 $15,000
Q1 2023 Apr 26, 2023	SELL	$182.66 - $235.53 $2,191 - $2,826	-12 Reduced 14.46%	71 $15,000
Q4 2022 Jan 12, 2023	BUY	$185.53 - $241.31 $556 - $723	3 Added 3.75%	83 $18,000
Q3 2022 Nov 08, 2022	BUY	$138.54 - $232.0 $11,083 - $18,560	80 New	80 $16,000
Q2 2020 Aug 10, 2020	SELL	$104.21 - $156.44 $625 - $938	-6 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$74.51 - $124.23 $447 - $745	-6 Reduced 50.0%	6 $1,000
Q3 2018 Nov 08, 2018	SELL	$87.52 - $122.67 $962 - $1,349	-11 Reduced 47.83%	12 $1,000
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $2,031 - $2,479	23 New	23 $2,000

645

109M

1.28M

1.22M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $32.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

Stay updated on Valley National Advisers Inc with notifications on news.